United States Non-Hodgkin Lymphoma Market to Reach $13.5 Billion by 2031 | AbbVie, Inc. , AstraZeneca plc, Bayer AG & Bristol-Myers Squibb Company.

The Global Non-Hodgkin Lymphoma Market reached USD 7.3 billion in 2023 and is projected to witness lucrative growth by reaching up to USD 13.5 billion by 2031. The global non-Hodgkin lymphoma market is expected to exhibit a CAGR of 8.2% during the forecast period 2024-2031

The Non-Hodgkin Lymphoma (NHL) Market covers therapies, including chemotherapy, targeted drugs, and immunotherapies, for the treatment of diverse lymphatic cancers. NHL is characterized by abnormal growth of lymphocytes, leading to immune system impairment. Increasing incidence of lymphoma, advances in personalized medicine, and development of novel immunotherapies drive market growth. Hospitals, cancer treatment centers, and research institutions are primary users. Improved diagnostic techniques and awareness campaigns also contribute to early detection and better treatment outcomes.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Non-Hodgkin Lymphoma Market Landscape:- https://datamintelligence.com/download-sample/non-hodgkin-lymphoma-market?rk

☛ Non-Hodgkin Lymphoma Market Recent Developments 2025:

United States: Recent Industry Developments in Non-Hodgkin Lymphoma

✅ In June 2025, the FDA approved tafasitamab (Monjuvi) in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma, offering a new treatment option for patients whose disease has returned or hasn't responded to previous therapies.

✅ In August 2025, the FDA granted regenerative medicine advanced therapy (RMAT) designation to GLPG5101, a second-generation anti-CD19/4-1BB CAR-T product candidate, for the treatment of patients with relapsed/refractory mantle cell lymphoma.

✅ In August 2025, the Lymphoma Research Foundation announced its 2025 grant class, awarding 24 research grants totaling $2.7 million to scientists based at leading cancer research institutions, supporting innovative lymphoma and chronic lymphocytic leukemia (CLL) research.

Japan: Recent Industry Developments in Non-Hodgkin Lymphoma

✅ In February 2025, the Ministry of Health, Labour, and Welfare in Japan approved epcoritamab (Epkinly) for the treatment of patients with relapsed or refractory grade 1 to 3A follicular lymphoma who have received two or more prior lines of therapy.

✅ In May 2025, Ono Pharmaceutical Co., Ltd. announced that the results from the open-label Phase 2 PROSPECT Study of tirabrutinib would be presented at the 2025 American Society for Clinical Oncology (ASCO) annual meeting, showcasing advancements in NHL treatment.

✅ In August 2025, the Ministry of Health, Labour and Welfare in Japan approved tazemetostat for relapsed or refractory EZH2 gene mutation-positive follicular lymphoma, providing a new therapeutic option for patients with this specific genetic mutation.

☛ Non-Hodgkin Lymphoma Market Trends:

The non-Hodgkin lymphoma market is driven by increasing incidence rates of hematologic cancers and the availability of innovative therapies such as monoclonal antibodies, CAR-T cell therapy, and targeted inhibitors. Early diagnosis and growing awareness are further supporting market expansion.

Emerging trends include personalized treatment approaches using genetic and molecular profiling, the rise of outpatient therapy options, and combination treatments aimed at improving survival rates and reducing side effects.

☛ Non-Hodgkin Lymphoma Market Competitve Landscape:

AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/non-hodgkin-lymphoma-market

☛ Segment Covered in the Non-Hodgkin Lymphoma Market:

By Disease Type: B-cell Lymphomas, T-cell Lymphoma

By Drug Class: Monoclonal Antibodies, Antibody-Drug Conjugates, BTK/BCL-2 Kinase Inhibitors, PI3 Kinase Inhibitors, Protease Inhibitors, PD1 Inhibitors, Immunomodulatory Drugs, Chemotherapy Agents, CAR T-Cell Therapy

By Route of Administration: Oral, Parenteral, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Non-Hodgkin Lymphoma Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=non-hodgkin-lymphoma-market

☛ Regional Analysis for Non-Hodgkin Lymphoma Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Non-Hodgkin Lymphoma Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Non-Hodgkin Lymphoma Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Non-Hodgkin Lymphoma Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.